Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS (NurOwn)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02017912
Recruitment Status : Completed
First Posted : December 23, 2013
Last Update Posted : July 18, 2018
Sponsor:
Information provided by (Responsible Party):
Brainstorm-Cell Therapeutics

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : March 2016
  Actual Study Completion Date : July 2016
  Certification/Extension First Submitted : July 15, 2018